Compare ETFs: IBB vs. LON:BTEC
IBB
LON:BTEC
Comparison
Average Return
In the past year, IBB returned a total of 52.67%, which is slightly lower than LON:BTEC's 54.00% return. Over the past 5 years, IBB has had annualized average returns of 3.91%, compared to 6.00% for LON:BTEC. These numbers are adjusted for stock splits and assume dividends are reinvested.
Top 25 Holdings
| IBB - iShares Biotechnology ETF | |||
|---|---|---|---|
| No. | Symbol | Name | Weight |
| 1 | AMGN | Amgen Inc. | 8.76% |
| 2 | VRTX | Vertex Pharmaceuticals Incorporated | 7.84% |
| 3 | GILD | Gilead Sciences, Inc. | 7.09% |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | 6.01% |
| 5 | ARGX | argenx SE | 3.49% |
| 6 | RVMD | Revolution Medicines, Inc. | 2.91% |
| 7 | NTRA | Natera, Inc. | 2.91% |
| 8 | ALNY | Alnylam Pharmaceuticals, Inc. | 2.36% |
| 9 | BIIB | Biogen Inc. | 2.34% |
| 10 | ILMN | Illumina, Inc. | 2.34% |
| 11 | ONC | BeOne Medicines AG | 2.02% |
| 12 | INCY | Incyte Corporation | 1.84% |
| 13 | UTHR | United Therapeutics Corporation | 1.65% |
| 14 | INSM | Insmed Incorporated | 1.65% |
| 15 | MRNA | Moderna, Inc. | 1.58% |
| 16 | ROIV | Roivant Sciences Ltd. | 1.38% |
| 17 | NBIX | Neurocrine Biosciences, Inc. | 1.24% |
| 18 | GMAB | Genmab A/S | 1.18% |
| 19 | ASND | Ascendis Pharma A/S | 1.17% |
| 20 | BBIO | BridgeBio Pharma, Inc. | 1.07% |
| 21 | EXEL | Exelixis, Inc. | 1.07% |
| 22 | MEDP | Medpace Holdings, Inc. | 1.05% |
| 23 | CRL | Charles River Laboratories International, Inc. | 0.96% |
| 24 | ARWR | Arrowhead Pharmaceuticals, Inc. | 0.89% |
| 25 | BMRN | BioMarin Pharmaceutical Inc. | 0.88% |
| View IBB holdings | |||
| LON:BTEC - iShares NASDAQ US Biotechnology UCITS ETF | |||
|---|---|---|---|
| No. | Symbol | Name | Weight |
| 1 | AMGN | Amgen Inc. | 8.01% |
| 2 | VRTX | Vertex Pharmaceuticals Incorporated | 8.00% |
| 3 | GILD | Gilead Sciences, Inc. | 7.36% |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | 4.90% |
| 5 | RVMD | Revolution Medicines, Inc. | 2.78% |
| 6 | ALNY | Alnylam Pharmaceuticals, Inc. | 2.51% |
| 7 | BIIB | Biogen Inc. | 2.14% |
| 8 | ILMN | Illumina, Inc. | 1.98% |
| 9 | RPRX | Royalty Pharma plc | 1.81% |
| 10 | ROIV | Roivant Sciences Ltd. | 1.74% |
| 11 | MRNA | Moderna, Inc. | 1.72% |
| 12 | ARGX | argenx SE | 1.67% |
| 13 | INSM | Insmed Incorporated | 1.65% |
| 14 | INCY | Incyte Corporation | 1.65% |
| 15 | UTHR | United Therapeutics Corporation | 1.60% |
| 16 | GH | Guardant Health, Inc. | 1.45% |
| 17 | VTRS | Viatris Inc. | 1.41% |
| 18 | NBIX | Neurocrine Biosciences, Inc. | 1.21% |
| 19 | ASND | Ascendis Pharma A/S | 1.13% |
| 20 | BBIO | BridgeBio Pharma, Inc. | 1.12% |
| 21 | JAZZ | Jazz Pharmaceuticals plc | 1.09% |
| 22 | MEDP | Medpace Holdings, Inc. | 1.08% |
| 23 | EXEL | Exelixis, Inc. | 0.99% |
| 24 | MDGL | Madrigal Pharmaceuticals, Inc. | 0.89% |
| 25 | AXSM | Axsome Therapeutics, Inc. | 0.83% |
| View LON:BTEC holdings | |||